<DOC>
	<DOCNO>NCT00199004</DOCNO>
	<brief_summary>The study evaluate efficacy tolerability intensify induction consolidation therapy combination rituximab CD20 positive standard risk patient . Thereafter patient receive additional consolidation reinduction cycle combine rituximab . In parallel minimal residual disease evaluate . After six month one year decision intensification discontinuation therapy make base result MRD evaluation</brief_summary>
	<brief_title>Trial Treatment Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Bprecursor ALL ( common / pre BALL ) Standard risk CD20 expression &gt; 20 % Ph/BCRABL negative Age 1565 year ( 5565 biologically young ) Written informed consent Severe complication due leukemia secondary illness Late relapse childhood ALL Cytostatic pretreatment Pregnancy Severe psychiatric illness circumstance may compromise cooperation patient inform consent Known severe allergy foreign protein</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
	<keyword>De novo</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Adult</keyword>
</DOC>